Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
The S&P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for...
The FDA has approved Eli Lilly's Kisunla (donanemab) for early symptomatic Alzheimer's disease. Kisunla, targeting amyl...
https://www.statnews.com/2024/07/03/ozempic-wegovy-naion-vision-loss-study/A new observational study on Wednesday reported for ...
https://nypost.com/2024/07/03/lifestyle/potential-link-between-ozempic-wegovy-and-serious-eye-condition-study/Researchers say t...
BMO Capital analyst Evan Seigerman maintains Eli Lilly and Co (NYSE:LLY) with a Outperform and maintains $1001 price target.
The treatment is intended for adults in the early symptomatic stages of Alzheimer's disease.
On Tuesday, the Dow Jones Industrial Average rose by 0.4%, closing at $39,331.85, while the S&P 500 also ended the day in p...
